Autres langues Kancera AB

Actions

KAN

SE0015658570

Marché Fermé - Nasdaq Stockholm Autres places de cotation 17:29:36 07/05/2024			Varia. 5j.	Varia. 1 janv.
1,402 ^SEK	-3,31%		-4,63%	-69,15%

03/05	Kancera AB (publ) rapporte des résultats positifs de l'étude clinique de phase I avec le KAND145 chez des sujets en santé	CI
23/02	Kancera AB (publ) publie ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Kancera meets the primary objectives of the KAND145 clinical phase I study	03/05
Kancera AB Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects	03/05
Kancera announces the outcome of the company's rights issue	20/03
Kancera publishes prospectus in connection with the company’s rights issue	01/03
Kancera resolves on a rights issue of approximately SEK 121.9 million	23/02
Interim Report Fourth Quarter 2023, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851	23/02
Kancera signs license agreement and obtains global commercial rights to the results from the FRACTAL study	23/02
Kancera AB Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
Kancera AB Signs A License Agreement with the University of Newcastle	23/02
Kancera AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	23/02
Kancera presents the statistical analysis of top line data from the FRACTAL study	06/02
Kancera AB Presents the statistical Analysis of Top Line Data from the FRACTAL Study	06/02
Kancera reports positive top line results from the FRACTAL study	20/12
Kancera AB Reports Positive Top Line Results from the FRACTAL Study	20/12
Kancera provides operational update in connection with release of financial interim report for third quarter 2023	17/11
Interim Report Third Quarter July 1 – September 30, 2023 Kancera AB (publ.), org.no. 556806-8851	17/11
Kancera AB Provides Operational Update Regarding Fractalkine Block Blockers KAN567 and KAND145	17/11
Kancera AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	17/11
Kancera reports that the phase I study of KAND145 has received regulatory approval	23/10/23
Kancera AB Receives Finnish Regulatory Agency Approval for Phase I Study of KAND145	23/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Kancera AB

Actions

KAN

SE0015658570

Autres langues

Filtres